nad bpc 157: Frequently asked questions

Increase to upper-range dosing (NMN 500mg or NR 1000mg daily) or switch to subcutaneous NAD+ for higher bioavailability. Oral precursors undergo first-pass metabolism, which can reduce effective NAD+ elevation by 30–50% depending on gut health and liver enzyme activity. If no improvement occurs after 4 weeks at upper-range oral dosing, subcutaneous delivery bypasses gastrointestinal limitations entirely. Also assess baseline mitochondrial stressors. Chronic inflammation, poor sleep, or high oxidative stress from environmental toxins can consume NAD+ faster than supplementation can replenish it.

Rotate injection sites more frequently (every dose rather than every 2–3 doses) and ensure reconstituted peptide is at room temperature before injection. Cold solution causes more local irritation. Verify bacteriostatic water was used for reconstitution (not sterile water), as the benzyl alcohol preservative reduces bacterial growth that can cause inflammation. If irritation persists, reduce dose to 200mcg twice daily and titrate upward over 7–10 days. BPC-157 is generally well-tolerated, but individual sensitivity varies.

Verify peptide quality and storage conditions first. BPC-157 degrades rapidly if stored above 8°C or exposed to light. A temperature excursion during shipping or improper refrigeration renders the peptide inactive. NAD+ precursors lose potency if stored in humid or warm environments. If storage was correct, consider that structural damage or metabolic dysfunction may exceed what nad+ bpc-157 stack cellular repair protocol 2026 alone can address. Chronic systemic inflammation, severe mitochondrial dysfunction, or advanced fibrosis may require additional therapeutic interventions alongside peptide stacking.

The synergy window closes. NAD+ bioavailability peaks at 60–90 minutes post-injection and declines with a 4-hour half-life. By the time you dose BPC-157 two or three hours later, mitochondrial NAD+ levels are already falling. You're still getting BPC-157's anabolic effects, but without the ATP surplus that allows maximum fibroblast activation and collagen deposition. The 30–45 minute gap is the intersection of rising NAD+ and active BPC-157. Deviating outside 15–75 minutes reduces measurable synergy by 30–50%.

You lose most of the synergistic benefit. NAD+ requires 20–30 minutes to reach mitochondria and begin restoring ATP production, while BPC-157 activates repair pathways within 15–20 minutes of injection. Simultaneous dosing means BPC-157 peaks before NAD+ has replenished cellular energy. The repair signaling occurs in an ATP-depleted environment, reducing collagen synthesis rates by 40–60% compared to sequential protocols. If you've already dosed them together, the individual benefits of each peptide remain, but the amplification effect that makes combination protocols worthwhile is largely absent.

Skip the missed dose and resume your regular schedule the next day. Do not double-dose to compensate. NAD+ in excess of mitochondrial capacity is excreted unused, and BPC-157 above 500mcg shows no additional benefit in most research models. Missing one or two doses in a 21-day acute injury protocol minimally impacts outcomes; missing more than three doses in the first two weeks reduces tissue repair velocity enough that extending the protocol by one additional week is typically necessary.